Profile: Paladin Labs Inc (PLB.TO)
PLB.TO on Toronto Stock Exchange
19.81CAD
11 Dec 2009
19.81CAD
11 Dec 2009
Price Change (% chg)
$-0.04 (-0.20%)
$-0.04 (-0.20%)
Prev Close
$19.85
$19.85
Open
$19.70
$19.70
Day's High
$19.81
$19.81
Day's Low
$19.70
$19.70
Volume
4,072
4,072
Avg. Vol
8,759
8,759
52-wk High
$20.50
$20.50
52-wk Low
$10.00
$10.00
Paladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The products offered by the Company include Tridural, Twinject, Seasonale, Plan B, Pennsaid, Metadol, Testim and Trelstar. Twinject is a pre-filled, pen size auto-injector with two doses of epinephrine for the emergency treatment of severe allergic reactions (anaphylaxis). Metadol is an analgesic in acute cancer pain, palliative care and chronic pain disorders. Pennsaid is a lotion for the treatment of symptoms of knee osteoarthritis. Seasonale is an extended-cycle oral contraceptive. Plan B is an emergency contraceptive. In December 2008, the Company acquired ViRexx Medical Corp, a Canada-based biotech company. In August 2009, the Company sold its T-ACT technology platform to IMBiotechnologies Ltd. In September 2009, the Company sold a pipeline of late-stage immunotherapy product candidates to Quest PharmaTech Inc.
Company Address
Paladin Labs Inc
6111 Royalmount Ave.
Suite 102
Montreal QC H4P 2T4
P: +1514.3401112
F: +1514.3444675
Company Web Links
| Name | Compensation |
|---|---|
| Wise, Ted | -- |
| Goodman, Jonathan | 908,900 |
| Sakhia, Samira | 504,650 |
| Beaudet, Mark | 538,750 |
| Larose, Patrice | 186,050 |





